IN184956B - - Google Patents
Info
- Publication number
- IN184956B IN184956B IN2408DE1995A IN184956B IN 184956 B IN184956 B IN 184956B IN 2408DE1995 A IN2408DE1995 A IN 2408DE1995A IN 184956 B IN184956 B IN 184956B
- Authority
- IN
- India
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/92—Oxygen atoms with hetero atoms directly attached to nitrogen atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Paints Or Removers (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19501481A DE19501481A1 (de) | 1995-01-19 | 1995-01-19 | 2,8-Disubstituierte Chinazolinone |
Publications (1)
Publication Number | Publication Date |
---|---|
IN184956B true IN184956B (fr) | 2000-10-07 |
Family
ID=7751829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2408DE1995 IN184956B (fr) | 1995-01-19 | 1995-12-26 |
Country Status (32)
Country | Link |
---|---|
US (1) | US5721238A (fr) |
EP (1) | EP0722937A1 (fr) |
JP (1) | JPH08253457A (fr) |
KR (1) | KR960029325A (fr) |
CN (1) | CN1134417A (fr) |
AR (1) | AR006738A1 (fr) |
AU (1) | AU704102B2 (fr) |
BG (1) | BG100293A (fr) |
BR (1) | BR9600148A (fr) |
CA (1) | CA2167345A1 (fr) |
CO (1) | CO4700522A1 (fr) |
CZ (1) | CZ16796A3 (fr) |
DE (1) | DE19501481A1 (fr) |
EE (1) | EE9600019A (fr) |
FI (1) | FI960227A (fr) |
HR (1) | HRP960004A2 (fr) |
HU (1) | HUP9600114A3 (fr) |
IL (1) | IL116770A (fr) |
IN (1) | IN184956B (fr) |
MA (1) | MA23780A1 (fr) |
NO (1) | NO307513B1 (fr) |
NZ (1) | NZ280831A (fr) |
PE (1) | PE66696A1 (fr) |
PL (1) | PL312352A1 (fr) |
RO (1) | RO117451B1 (fr) |
RU (1) | RU2158733C2 (fr) |
SG (1) | SG34377A1 (fr) |
SK (1) | SK7796A3 (fr) |
SV (1) | SV1996000005A (fr) |
TR (1) | TR199600029A2 (fr) |
YU (1) | YU1496A (fr) |
ZA (1) | ZA96397B (fr) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5858694A (en) * | 1997-05-30 | 1999-01-12 | Cell Pathways, Inc. | Method for identifying compounds for inhibition of cancerous lesions |
CA2238283C (fr) | 1997-05-30 | 2002-08-20 | Cell Pathways, Inc. | Methode d'identification de composes visant a inhiber les lesions neoplasiques, compositions pharmaceutiques a prtir de ces composes et compositions pour traiter les lesions neoplasiques |
US20020025969A1 (en) * | 1997-07-09 | 2002-02-28 | Wolf-Georg Forssmann | Use of phosphordiesterase inhibitors in the treatment of prostatic diseases |
US6410584B1 (en) | 1998-01-14 | 2002-06-25 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells with indole derivatives |
US6426084B1 (en) | 2000-06-19 | 2002-07-30 | Neal R. Cutler | Treatment of sexual dysfunction in certain patient groups |
US6194433B1 (en) * | 1998-10-05 | 2001-02-27 | Neal R. Cutler | Sexual dysfunction in females |
US6110489A (en) * | 1998-05-01 | 2000-08-29 | Cutler; Neal R. | Use of quinolines and quinolones to treat male erectile dysfunction |
US6132757A (en) | 1998-05-01 | 2000-10-17 | Neal R. Cutler | Treatment of sexual dysfunction in certain patient groups |
US6132753A (en) * | 1998-05-01 | 2000-10-17 | Neal R. Cutler | Treatment of sexual dysfunction in certain patient groups |
US6187790B1 (en) | 1999-03-04 | 2001-02-13 | Neal R. Cutler | Use of cilostazol for treatment of sexual dysfunction |
US6130053A (en) * | 1999-08-03 | 2000-10-10 | Cell Pathways, Inc. | Method for selecting compounds for inhibition of neoplastic lesions |
US6200771B1 (en) | 1998-10-15 | 2001-03-13 | Cell Pathways, Inc. | Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia |
US6133271A (en) * | 1998-11-19 | 2000-10-17 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives |
US6187779B1 (en) | 1998-11-20 | 2001-02-13 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives |
US6369092B1 (en) | 1998-11-23 | 2002-04-09 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted benzimidazole derivatives |
US6486155B1 (en) | 1998-11-24 | 2002-11-26 | Cell Pathways Inc | Method of inhibiting neoplastic cells with isoquinoline derivatives |
US6077842A (en) * | 1998-11-24 | 2000-06-20 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives |
US6034099A (en) * | 1998-11-24 | 2000-03-07 | Cell Pathways, Inc. | Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones |
US6025394A (en) | 1999-01-29 | 2000-02-15 | Cell Pathways, Inc. | Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols |
US6020379A (en) * | 1999-02-19 | 2000-02-01 | Cell Pathways, Inc. | Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia |
US6303135B1 (en) | 1999-07-08 | 2001-10-16 | Neal R. Cutler | Use of quinolines and quinolones to treat male erectile dysfunction |
US6555547B1 (en) | 2000-02-28 | 2003-04-29 | Cell Pathways, Inc. | Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative |
US6569638B1 (en) | 2000-03-03 | 2003-05-27 | Cell Pathways, Inc | Method for screening compounds for the treatment of neoplasia |
EP1316316B1 (fr) * | 2000-09-06 | 2012-04-04 | Mitsubishi Tanabe Pharma Corporation | Preparations administrees par voie orale |
US6562838B2 (en) * | 2001-01-26 | 2003-05-13 | R. T. Alamo Ventures I, L.L.C. | Treatment of cardiovascular disease with quinolinone enantiomers |
ATE472319T1 (de) | 2001-02-15 | 2010-07-15 | Mitsubishi Tanabe Pharma Corp | Tabletten, die in der mundhöhle schnell zerfallen |
BR0214606A (pt) * | 2001-11-30 | 2004-09-14 | Pfizer Prod Inc | Processos para a preparação de derivados bicìclicos substituìdos para o tratamento de crescimento de célula anormal |
US7208516B2 (en) | 2002-03-20 | 2007-04-24 | Celgene Corporation | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US7276529B2 (en) | 2002-03-20 | 2007-10-02 | Celgene Corporation | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
CA2494061C (fr) | 2002-07-31 | 2011-06-14 | Wayne R. Danter | Inhibiteurs de proteine tyrosine kinase |
EP1551824B1 (fr) | 2002-10-09 | 2007-12-12 | Critical Outcome Technologies, Inc. | Inhibiteurs de proteine tyrosine kinase |
EP1578757B1 (fr) * | 2002-12-27 | 2014-10-22 | Janssen Infectious Diseases BVBA | Substrats fluorogeniques enzymatiques et methodes de preparation |
CN100506802C (zh) * | 2004-06-04 | 2009-07-01 | 中国科学院上海药物研究所 | 一类甲酰肽样受体-1调节剂、其制备方法和用途 |
JP2010505811A (ja) * | 2006-10-04 | 2010-02-25 | ファイザー・プロダクツ・インク | カルシウム受容体アンタゴニストとしてのピリド[4,3−d]ピリミジン−4(3H)−オン誘導体 |
CA2673683C (fr) | 2007-01-11 | 2014-07-29 | Critical Outcome Technologies, Inc. | Composes et methode de traitement un cancer |
US8138191B2 (en) | 2007-01-11 | 2012-03-20 | Critical Outcome Technologies Inc. | Inhibitor compounds and cancer treatment methods |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
AU2008261102B2 (en) | 2007-06-04 | 2013-11-28 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
CN101429166B (zh) * | 2007-11-07 | 2013-08-21 | 上海特化医药科技有限公司 | 喹唑啉酮衍生物及其制备方法和用途 |
EP2225226B1 (fr) | 2007-12-26 | 2016-08-17 | Critical Outcome Technologies, Inc. | Composés et leur utilisation dans un procédé pour le traitement du cancer |
EP2328910B1 (fr) | 2008-06-04 | 2014-08-06 | Synergy Pharmaceuticals Inc. | Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles |
EP3241839B1 (fr) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres |
CA2745694C (fr) | 2008-12-03 | 2018-03-27 | Synergy Pharmaceuticals, Inc. | Formulations d'agonistes de guanylate cyclase c et methode d'utilisation |
EP2552915B1 (fr) | 2010-04-01 | 2017-07-19 | Critical Outcome Technologies Inc. | Composés pour le traitement du vih |
JP6393037B2 (ja) | 2010-09-15 | 2018-09-19 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼcアゴニストの製剤および使用方法 |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
WO2014151206A1 (fr) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonistes de la guanylate cyclase et leurs utilisations |
EP3689420A1 (fr) * | 2014-01-23 | 2020-08-05 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Dérivés de l'icariine pour leur utilisation dans le traitement du syndrome myélodysplasique |
JP6687550B2 (ja) | 2014-06-23 | 2020-04-22 | セルジーン コーポレイション | 肝疾患又は肝機能異常を治療するためのアプレミラスト |
CN110590769B (zh) * | 2019-06-13 | 2021-09-24 | 中山大学 | 一对喹唑啉酮生物碱对映体及其制备方法和应用 |
WO2024026424A1 (fr) * | 2022-07-27 | 2024-02-01 | Black Diamond Therapeutics, Inc. | Dérivés de quinazolinone et utilisations associées |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3169129A (en) * | 1963-05-10 | 1965-02-09 | American Cyanamid Co | 2-ortho-hydroxy-phenyl-4-(3h)-quinazolinones |
US4431440A (en) * | 1981-02-20 | 1984-02-14 | American Cyanamid Company | Method to alter or control the development and/or the life cycle of various plant species |
GB9126260D0 (en) * | 1991-12-11 | 1992-02-12 | Pfizer Ltd | Therapeutic agents |
US5294612A (en) * | 1992-03-30 | 1994-03-15 | Sterling Winthrop Inc. | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof |
-
1995
- 1995-01-19 DE DE19501481A patent/DE19501481A1/de not_active Withdrawn
- 1995-12-26 IN IN2408DE1995 patent/IN184956B/en unknown
-
1996
- 1996-01-05 HR HR19501481.2A patent/HRP960004A2/hr not_active Application Discontinuation
- 1996-01-08 EP EP96100154A patent/EP0722937A1/fr not_active Withdrawn
- 1996-01-11 US US08/584,865 patent/US5721238A/en not_active Expired - Fee Related
- 1996-01-12 YU YU1496A patent/YU1496A/sh unknown
- 1996-01-15 AU AU40980/96A patent/AU704102B2/en not_active Ceased
- 1996-01-15 TR TR96/00029A patent/TR199600029A2/xx unknown
- 1996-01-16 CA CA002167345A patent/CA2167345A1/fr not_active Abandoned
- 1996-01-16 IL IL11677096A patent/IL116770A/xx active IP Right Grant
- 1996-01-16 NZ NZ280831A patent/NZ280831A/en unknown
- 1996-01-16 RO RO96-00077A patent/RO117451B1/ro unknown
- 1996-01-17 SG SG1996000263A patent/SG34377A1/en unknown
- 1996-01-17 JP JP8022973A patent/JPH08253457A/ja active Pending
- 1996-01-17 PL PL96312352A patent/PL312352A1/xx unknown
- 1996-01-17 FI FI960227A patent/FI960227A/fi unknown
- 1996-01-18 EE EE9600019A patent/EE9600019A/xx unknown
- 1996-01-18 RU RU96100854/04A patent/RU2158733C2/ru active
- 1996-01-18 CZ CZ96167A patent/CZ16796A3/cs unknown
- 1996-01-18 SK SK77-96A patent/SK7796A3/sk unknown
- 1996-01-18 KR KR1019960001004A patent/KR960029325A/ko not_active Application Discontinuation
- 1996-01-18 ZA ZA96397A patent/ZA96397B/xx unknown
- 1996-01-18 NO NO960222A patent/NO307513B1/no unknown
- 1996-01-18 BR BR9600148A patent/BR9600148A/pt active Search and Examination
- 1996-01-18 MA MA24135A patent/MA23780A1/fr unknown
- 1996-01-18 BG BG100293A patent/BG100293A/xx unknown
- 1996-01-19 SV SV1996000005A patent/SV1996000005A/es unknown
- 1996-01-19 PE PE1996000044A patent/PE66696A1/es not_active Application Discontinuation
- 1996-01-19 HU HU9600114A patent/HUP9600114A3/hu unknown
- 1996-01-19 CO CO96002168A patent/CO4700522A1/es unknown
- 1996-01-19 AR ARP960101087A patent/AR006738A1/es unknown
- 1996-01-19 CN CN96101906A patent/CN1134417A/zh active Pending